1-3 of 3
Keywords: Biosimilar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (Retacrit TM ) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis

Subject Area:
Nephrology
Ravi Thadhani, Ruffy Guilatco, Jeffrey Hymes, Franklin W. Maddux, Ajay Ahuja
Journal: American Journal of Nephrology
Am J Nephrol (2018) 48 (3): 214–224.
https://doi.org/10.1159/000492621
Published Online: 07 September 2018
... in patients switched from epoetin alfa reference product (Epogen®) to epoetin alfa-epbx (Retacrit TM ; a biosimilar to US-licensed Epogen®/Procrit®). Methods: This randomized, open-label, non-inferiority study was conducted at Fresenius Medical Care North America (FMCNA) hemodialysis centers. Patients...
View article titled, Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (Retacrit TM ) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis
Open the PDF for Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (Retacrit TM ) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis in another window
Journal Articles

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease

Subject Area:
Nephrology
Matthew R. Weir, Pablo E. Pergola, Rajiv Agarwal, Jeffrey C. Fink, Nelson P. Kopyt, Ajay K. Singh, Jayant Kumar, Susanne Schmitt, Gregor Schaffar, Anita Rudy, Jim P. McKay, Radmila Kanceva
Journal: American Journal of Nephrology
Am J Nephrol (2017) 46 (5): 364–370.
https://doi.org/10.1159/000481736
Published Online: 30 October 2017
...Matthew R. Weir; Pablo E. Pergola; Rajiv Agarwal; Jeffrey C. Fink; Nelson P. Kopyt; Ajay K. Singh; Jayant Kumar; Susanne Schmitt; Gregor Schaffar; Anita Rudy; Jim P. McKay; Radmila Kanceva Background: HX575 (biosimilar epoetin alfa) was approved in Europe in 2007 for the treatment of chronic kidney...
View article titled, A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed <span class="search-highlight">Biosimilar</span>) with Epoetin Alfa in Patients with End-Stage Renal Disease
Open the PDF for A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed <span class="search-highlight">Biosimilar</span>) with Epoetin Alfa in Patients with End-Stage Renal Disease in another window
Journal Articles

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

Subject Area:
Nephrology
Kamyar Kalantar-Zadeh
Journal: American Journal of Nephrology
Am J Nephrol (2017) 45 (3): 235–247.
https://doi.org/10.1159/000455387
Published Online: 01 February 2017
... budgets around the world. Summary: Biosimilars, or biologic drugs that are designed to be highly similar to approved reference biologic drugs, have been available in Europe for more than 10 years with no unusual or unexpected effects compared to their reference biologics whose patents have expired. Given...
View article titled, History of Erythropoiesis-Stimulating Agents, the Development of <span class="search-highlight">Biosimilars</span>, and the Future of Anemia Treatment in Nephrology
Open the PDF for History of Erythropoiesis-Stimulating Agents, the Development of <span class="search-highlight">Biosimilars</span>, and the Future of Anemia Treatment in Nephrology in another window